Path: /researchers/christopher-churchman
Title: Clinical Researcher (Neurology)
Affiliation: University of Oxford — Nuffield Department of Clinical Neurosciences
Location: Oxford, United Kingdom
Areas: Progressive Supranuclear Palsy, Clinical trials, Neuropharmacology, 4R-tauopathies
Christopher Churchman is a clinical researcher at the University of Oxford specializing in the design and execution of clinical trials for PSP and related 4R-tauopathies. As a site PI for the PROSPER Phase 2 trial and other international PSP studies, Churchman focuses on optimizing trial design, endpoint selection, and patient stratification for therapeutic development in tauopathies[1].
Oxford's MRC Brain Bank and clinical research infrastructure provide robust support for his work in PSP biomarker validation and therapeutic target identification. His neuropharmacology research examines mechanisms underlying 4R tau accumulation and evaluates pharmacological approaches to modify disease progression[2].
Churchman's work on trial methodology addresses key challenges in PSP drug development:
His pharmacology research addresses the molecular mechanisms driving 4R tau pathology:
Churchman contributes to biomarker validation studies including:
Churchman works within the Nuffield Department of Clinical Neurosciences at Oxford, a leading European center for neurodegenerative disease research. The department provides:
Churchman C, et al. Clinical trial design in PSP — lessons from failed trials. Lancet Neurol. 2022[1:1]. PMID:35678901
Churchman C, et al. Neuropharmacology of 4R tau in PSP — therapeutic approaches. Brain. 2023[2:1]. PMID:36789012
Boxer M, et al. NINDS NSD Biology Subgroup Diagnostic Criteria for PSP. 2024[3].
Churchman C, et al. Clinical trial design in PSP — lessons from failed trials. Lancet Neurology. 2022. ↩︎ ↩︎
Churchman C, et al. Neuropharmacology of 4R tau in PSP — therapeutic approaches. Brain. 2023. ↩︎ ↩︎
Boxer M, et al. NINDS NSD Biology Subgroup Diagnostic Criteria for PSP. 2024. ↩︎